{
    "metadataAttributes": {
    "title": "Topical Ocular Delivery of NSAIDs",
    "authors": "Munish Ahuja, Avinash S. Dhake, Surendra K. Sharma, Dipak K. Majumdar",
    "keywords": "NSAIDs, bromfenac, anti-inflammatory, ophthalmology, topical administration, nanoparticles, COX-2, ocular inflammation, ophthalmic formulations",
    "description": "Review of NSAIDs in ocular administration, focusing on bromfenac and innovative formulations.",
    "publication_date": "2008-04-25",
    "categories": "Pharmacology, Ophthalmology, Non-steroidal anti-inflammatory drugs, Biomedical research",
    "language": "English",
    "reference": "DOI: 10.1208/s12248-008-9024-9",
    "mechanism_of_action": "Bromfenac selectively inhibits COX-2, reducing prostaglandin production in ocular tissues.",
    "physicochemical_attributes": "pH around 8.3, use of cyclodextrins, compatibility with polysorbate 80, incompatibility with benzalkonium chloride",
    "comparative_efficacy": "Bromfenac is 3.7 times more potent than diclofenac and 18 times more potent than ketorolac.",
    "clinical_uses": "Postoperative inflammation and pain control after cataract surgeries."
    }
}
  